NCT00562575View on ClinicalTrials.gov

Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Hypertriglyceridemia
Interventions
DRUG

SLx-4090

DRUG

Placebo

Trial Locations (1)

D-41460

FOCUS Clinical Drug Development GmbH, Neuss

Sponsors
All Listed Sponsors
lead

Response Pharmaceuticals

INDUSTRY

NCT00562575 - Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides | Biotech Hunter | Biotech Hunter